久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

Basic Info
  • Grade: Pharmaceutical Grade

    Factory Location: Guangzhou, China

    Main Sales Markets: Asia,Middle East,Africa

  • Monthly Production Capacity: 1000kgs

  • Sample Provided: no

    Name: Flibanserin HCl

    MF: C20H22ClF3N4O

    MW: 426.86

    CAS:147359-76-0

    Character: white powder

    Purity(HPLC): 99.5%

     

    Flibanserin (INN, USAN) (developmental code name BIMT-17; proposed trade names Girosa and Addyi) is a drug that is being studied as a non-hormonal treatment for pre-menopausal women with hypoactive sexual desire disorder (HSDD). Development by Boehringer Ingelheim was halted in October 2010 following a negative evaluation by the U.S. Food and Drug Administration. The rights to the drug were then transferred to Sprout Pharmaceuticals, which is continuing the drug development process. On June 4, 2015, the panel to the FDA recommended approval of the drug by 18–6.

Send your message to this supplier
  • From:
  • To:
    Guangzhou Congen Pharmatec Co.,Ltd.
  • Send a Copy to this Email
  • Message:
    Upload Images / Files
    -?Supports?jpg,?jpeg,?png,
    ?gif,?pdf,?doc,?docx,
    ?xls,?xlsx,?txt,?rar?and?zip
    -?Max?upload?3?files;
    ?Max??total?size:?3MB
    (0/3)

    Enter between 20 to 4,000 characters.This is not what you are looking for ? Post a Sourcing Request Now

  • Verification:
PharmaSources Customer Service